[
  {
    "categoryName": "Companies",
    "groups": [
      {
        "group": "Pfizer",
        "items": [
          {
            "item": "Flu vaccines",
            "description": "Prevnar shots",
            "details": {
              "Prevnar-20": {
                "text": "20-strain pneumococcal shot OK'd for infants and children in April 2023 and OK'd in adults in 2021.",
                "collapsible": false
              },
              "Prevnar-13": {
                "text": "Protects against 13 bacteria strains.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Covid therapies",
            "description": "",
            "details": {
              "Paxlovid": {
                "text": "COVID antiviral",
                "collapsible": false
              },
              "Comirnaty": {
                "text": "COVID-19 vaccine with partner BioNTech",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "Novo Nordisk",
        "items": [
          {
            "item": "GLP-1 agonists",
            "description": "description",
            "details": {
              "Victoza, Saxenda (liraglutide)": {
                "text": "Victoza - daily shot for diabetes approved in 2010Saxenda - Novo pioneered the use of insulin-stimulating diabetes drugs as weight loss treatments when it launched a high-dose version Victoza as Saxenda in 2014.",
                "collapsible": false
              },
              "Ozempic": {
                "text": "Approved in 2017 for Type 2 diabetes - injectable semaglutide in 0.5, 1.0 and 2.0 mg doses",
                "collapsible": false
              },
              "Rybelsus": {
                "text": "Approved 2019 for Type 2 diabetes - pill of semaglutide in 3, 7 and 14 mg doses",
                "collapsible": false
              },
              "Wegovy": {
                "text": "Approved in 2021 for weight loss - injectable semaglutide in escalating doses to begin and then 2.4 mg for maintenance",
                "collapsible": false
              },
              "Experimental obesity pill": {
                "text": "Once daily pill of 50 mg semaglutide Novo plans to ask for approval after a Phase 3 study showed it help patients lose an average 15.1% of weight",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "Novartis",
        "items": [
          {
            "item": "Restructuring",
            "description": "In 2022 Novartis narrowed its focus to these five drug areas",
            "details": {
              "Restructuring": {
                "text": "It trimmed [10% of pipeline](https://www.biopharmadive.com/news/novartis-narrows-drug-pipeline-1q23-earnings/648522/) in early 2023 as part of a [restructuring](https://www.biopharmadive.com/news/novartis-restructuring-executives-tsai-departure/621485/) that has laid off [thousands of employees](https://www.biopharmadive.com/news/novartis-restructuring-layoffs-switzerland/626265/) | [is spinning out its generics division Sandoz](https://www.biopharmadive.com/news/novartis-sandoz-spinoff-generic-drug/630492/) | Halted work on medicines for [sickle cell disease](https://www.biopharmadive.com/news/intellia-graphite-sangamo-sickle-cell-gene-therapy-discontinue/643400/) and [Huntington’s disease](https://www.biopharmadive.com/news/novartis-huntingtons-drug-development-stop-branaplam/641747/) and gave up the licensing rights for a drug aimed at [a type of fatty liver disease](https://www.biopharmadive.com/news/novartis-nash-deal-termination-pliant/643530/).",
                "collapsible": false
              }
            }
          },
          {
            "item": "Cardiovascular",
            "description": "",
            "details": {
              "Entresto": {
                "text": "Heart failure drug had sluggish launch after it was OK'd in 2025, but broke $1B in 2019 and by 2022 was a topseller | First approved for patients with “reduced ejection fraction\", expanded to \"preserved ejection fraction\" in 2021 — first drug to be cleared for both groups.",
                "collapsible": false
              },
              "Leqvio": {
                "text": "RNA interference therapy to reduce LDL cholesterol via in-office injection. | Works like Amgen’s Repatha and Sanofi/Regeneron's Praluent. Approved in [Dec 2021](https://www.biopharmadive.com/news/novartis-leqvio-inclisiran-fda-approval-cholesterol-heart/611170/) | Invented by Alnylam and bought via developer The Medicines Co.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Immunology",
            "description": "",
            "details": {
              "Cosentyx": {
                "text": "Inflammatory disease drug second highest seller in early 2022 | Works by inhibiting a pro-inflammatory protein called interleukin-17A, or IL-17A. | Competitors: Eli Lilly’s Taltz (ixekizumab) also targets IL-17A, while Bausch Health’s Siliq (brodalumab) focuses specifically on IL-17.",
                "collapsible": false
              },
              "Xolair": {
                "text": "Roche (Genentech)/Novartis biological asthma drug. Also can be used for chronic hives known in clinical parlance as chronic idiopathic urticaria [history](https://www.drugs.com/history/xolair.html)",
                "collapsible": false
              },
              "Ilaris": {
                "text": "Sold for several fever syndromes and uncommon forms of arthritis. The drug, canakinumab, binds to a cytokine protein called IL-1ß which controls inflammatory signaling, and blocking it was thought to suppress pro-tumor inflammation. [Has failed to win broader use](https://www.biopharmadive.com/news/novartis-canakinumab-lung-cancer-phase-3-study-failure/629636/) to reduce heart risk and as a cancer drug.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Neuroscience",
            "description": "",
            "details": {
              "Gilenya": {
                "text": "Multiple sclerosis drug facing generics competition. First approved in Sept 2010, was the first oral drug for the relapsing-remitting form of multiple sclerosis and made Novartis one of several major players in multiple sclerosis. | Acts on the sphingosine 1-phosphate (S1P) receptor | Supreme Ct. in April 2023 refused to stop a lower court's ruling canceling its patent.",
                "collapsible": false
              },
              "Zolgensma": {
                "text": "Gene therapy for rare condition called spinal muscular atrophy. see Medicines | Approved in [2019 ](https://www.biopharmadive.com/news/novartis-gene-therapy-zolgensma-approved-fda/554961/)a year after Novartis acquired it from AveXis for about $9B",
                "collapsible": false
              },
              "Kesimpta": {
                "text": "Self-administered injectable for relapsing form of MS, the most common form of the disease, an advantage Novartis sees over Roche's Ocrevus that is infused 2X/yr at doc. | OK'd in [Aug 2020](https://www.biopharmadive.com/news/novartis-fda-approves-multiple-sclerosis-drug-kesimpta/583901/) | Part of a shift away from older medicines like interferons towards pills and monoclonal antibodies since 2010 like Biogen's Tecfidera and Ocrevus. | Low-dose formulation of old leukemia drug Arzerra that, like Ocrevus, targets CD20 on B cells that can delay MS symptoms.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Solid Tumor",
            "description": "",
            "details": {
              "Tafinlar + Mekinist": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Kisqali": {
                "text": "Breast cancer treatment",
                "collapsible": false
              },
              "Piqray": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Pluvicto": {
                "text": "Prostate cancer drug",
                "collapsible": false
              }
            }
          },
          {
            "item": "Hematology",
            "description": "",
            "details": {
              "Promacta/Revolade": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Tasigna": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Jakavi": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Scemblix": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "Other brands",
            "description": "Lucentis, Xiidra, Sandostatin",
            "details": {
              "Lucentis": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Xiidra": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Sandostatin": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "Eli Lilly",
        "items": [
          {
            "item": "GLP-1 agonists",
            "description": "Glucagon-like peptide-1 receptor agonists",
            "details": {
              "Trulicity (dulaglutide)": {
                "text": "Weekly shot for Type 2 diabetes approved in 2014",
                "collapsible": false
              },
              "Mounjaro (tirzepatide)": {
                "text": "Shot approved to control diabetes in May 2022Works by stimulating two hormones, GLP-1 and GIP",
                "collapsible": false
              }
            }
          },
          {
            "item": "Other diabetes",
            "description": "",
            "details": {
              "Basaglar": {
                "text": "Long-acting human insulin analog. Partner Boehringer Ingelheim",
                "collapsible": false
              },
              "Humalog": {
                "text": "Human insulin analogs",
                "collapsible": false
              },
              "Jardiance": {
                "text": "Approved for type 2 diabetes. Cleared expanded use in heart failure patients. Partner Boehringer Ingelheim",
                "collapsible": false
              }
            }
          },
          {
            "item": "Oncology",
            "description": "",
            "details": {
              "Alimta": {
                "text": "",
                "collapsible": false
              },
              "Cyramza": {
                "text": "",
                "collapsible": false
              },
              "Erbitux": {
                "text": "",
                "collapsible": false
              },
              "Jaypirca": {
                "text": "",
                "collapsible": false
              },
              "Retevmo": {
                "text": "",
                "collapsible": false
              },
              "Tyvyt": {
                "text": "",
                "collapsible": false
              },
              "Verzenio": {
                "text": "",
                "collapsible": false
              }
            }
          },
          {
            "item": "Immunology",
            "description": "",
            "details": {
              "Olumiant": {
                "text": "",
                "collapsible": false
              },
              "Taltz": {
                "text": "",
                "collapsible": false
              }
            }
          },
          {
            "item": "Neuroscience",
            "description": "",
            "details": {
              "Cymbalta": {
                "text": "",
                "collapsible": false
              },
              "Emgality": {
                "text": "",
                "collapsible": false
              },
              "Zyprexa": {
                "text": "",
                "collapsible": false
              }
            }
          },
          {
            "item": "Other products",
            "description": "",
            "details": {
              "Covid therapies": {
                "text": "bamlanivimab and etesevimab, and bebtelovimab",
                "collapsible": false
              },
              "Cialis": {
                "text": "",
                "collapsible": false
              },
              "Forteo": {
                "text": "",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "AstraZeneca",
        "items": [
          {
            "item": "Oncology",
            "description": "xxxxxxxxxxxxxxxxx",
            "details": {
              "Tagrisso": {
                "text": "Accelerated OK in 2015 for EGFR mutation-positive non-small cell lung cancer, full OK in 2017m later expanded to first line and adjuvant [history](https://www.drugs.com/history/tagrisso.html) | Oral tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR)  | 2023 [results](https://www.biopharmadive.com/news/astrazeneca-tagrisso-imfinzi-early-lung-cancer/644565/) added to debate whether cancer drugs' ability to stop tumors is proxy for ability to keep patients alive, ie. translating measures known as “disease-free survival” or “event-free survival\" in early testing before accumulate evidence of extending lives.",
                "collapsible": true
              },
              "Imfinzi": {
                "text": "xxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Lynparza": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Calquence": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Enhertu": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Orpathys": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Zoladex": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Faslodex": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Iressa": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Arimidex": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Casodex": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Notes on cancer": {
                "text": "Stat: Since 2014, AstraZeneca has brought eight new cancer medicines to market. Several have become mainstay products in the field of targeted therapy, including Lynparza, Enhertu, and Tagrisso. | Susan Galbraith leads cancer R&D and Pascal Soriot became CEO in 2021, flipped culture to science over finances.",
                "collapsible": true
              }
            }
          },
          {
            "item": "Cardio Renal Metabolic",
            "description": "xxxxxxxxxxxxxxxxx",
            "details": {
              "Farxiga": {
                "text": "xxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Brilinta": {
                "text": "xxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Lokelma": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Roxadustat": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Andexxa": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Crestor": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Seloken/Toprol-XL": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Bydureon": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Onglyza": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Notes on cancer": {
                "text": "Stat: Since 2014, AstraZeneca has brought eight new cancer medicines to market. Several have become mainstay products in the field of targeted therapy, including Lynparza, Enhertu, and Tagrisso. | Susan Galbraith leads cancer R&D and Pascal Soriot became CEO in 2021, flipped culture to science over finances.",
                "collapsible": true
              }
            }
          },
          {
            "item": "Respiratory & Immunology",
            "description": "xxxxxxxxxxxxxxxxx",
            "details": {
              "Symbicort": {
                "text": "xxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Fasenra": {
                "text": "xxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Breztri": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Saphnelo": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Tezspire": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Pulmicort": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Daliresp/Daxas": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Bevespi": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "Vaccines & Immune Therapies",
            "description": "xxxxxxxxxxxxxxxxx",
            "details": {
              "Vaxzevria": {
                "text": "xxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Evusheld": {
                "text": "xxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Synagis": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "FluMist": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "Rare Disease",
            "description": "xxxxxxxxxxxxxxxxx",
            "details": {
              "Soliris": {
                "text": "xxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Ultomiris": {
                "text": "xxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Strensiq": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Koselugo": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "Kanuma": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "Other",
            "description": "",
            "details": {
              "Nexium": {
                "text": "xxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          }
        ]
      }
    ]
  },
  {
    "categoryName": "Diseases",
    "groups": [
      {
        "group": "Neuro-degenerative",
        "items": [
          {
            "item": "Alzheimer's disease",
            "description": "xxxxxxxxxxx",
            "details": {
              "xxxxxxxxxxxxxxxxxxxxx": {
                "text": "xxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "xxxxxxxxxx": {
                "text": "xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "ALS",
            "description": "Amyotrophic lateral sclerosis",
            "details": {
              "Failed drugs": {
                "text": "ALS has frustrated researchers for decades. In 2017, this group cited [more than 60 molecules](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360725/) that had been studied and “overwhelming majority” resulted in disappointment. | Study failures in recent years include: [Biogen](https://www.biopharmadive.com/news/biogen-ionis-als-drug-study-failure-genetic/621107/), [Cytokinetics](https://www.biopharmadive.com/news/cytokinetics-als-trial-discontinuation-courage-study/646550/), [Alexion Pharmaceuticals](https://www.biopharmadive.com/news/alexion-discontinues-als-drug-trial-due-to-lack-of-efficacy/605412/) [Biohaven Pharmaceuticals](https://www.biopharmadive.com/news/biohaven-als-healey-trial-verdiperstat/632974/)  [Wave Life](https://www.biopharmadive.com/news/wave-als-dementia-drug-discontinue-trial-setback/651017/) [Apellis Pharmaceuticals](https://www.biopharmadive.com/news/apellis-als-pegcetacoplan-study-failure/651257/)",
                "collapsible": true
              },
              "Approvals": {
                "text": "[Rilutek](https://www.alsclinic.pitt.edu/patient-issues/are-there-treatments) cleared in 1995 | [Radicava](https://www.als.org/navigating-als/living-with-als/fda-approved-drugs/edaravone) OK'd in 2017. | Amylyx’s Relyvrio accelerated OK in [Sept 2022](https://www.biopharmadive.com/news/amylyx-fda-approval-als-drug-relyvrio/632592/) | Biogen's Qalsody for small group with specific mutation in [April 2023](https://www.biopharmadive.com/news/biogen-tofersen-als-fda-approval-decision/648235/) | None of the approved drugs can reverse or cure the condition, at best giving patients a chance to slow their decline and live longer.",
                "collapsible": true
              },
              "Disease notes": {
                "text": "Also known as Lou Gehrig’s disease, the disorder attacks nerve cells in the brain and spinal cord, causing a loss of muscle control that eventually affects the whole body, even robbing a person of the ability to breathe. The average [survival time](https://www.als.org/understanding-als/stages) after diagnosis is three years. | In part pushed by patients, the FDA and NIH in 2022 launched an [initiative](https://www.biopharmadive.com/news/fda-nih-neurodegenerative-diseases-initiative/631945/) focused on ALS and other rare brain conditions",
                "collapsible": true
              }
            }
          }
        ]
      },
      {
        "group": "Cardio-vascular",
        "items": [
          {
            "item": "Cardiology",
            "description": "xxxxxxxxxxx",
            "details": {
              "Investment": {
                "text": "Venture firms have historically [hesitated to invest in heart drugs](https://www.biopharmadive.com/news/pharmacquired-heart-drug-deals-myokardia/586434/). They’re expensive to develop and test and, in recent years, have taken a backseat to research areas like cancer and rare diseases, which can have shorter development timelines.",
                "collapsible": true
              },
              "xxxxxxxxxx": {
                "text": "xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "another cardio-vasc",
            "description": "xxxxxxxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "xxxxxxxxxxx": {
                "text": "xxxxxxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              },
              "xxxxxxxxxxxxxx": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          }
        ]
      }
    ]
  },
  {
    "categoryName": "Medicines",
    "groups": [
      {
        "group": "CAR-T",
        "items": [
          {
            "item": "Kymriah",
            "description": "(Novartis)   First CAR-T ever approved by FDA in Aug 2017",
            "details": {
              "Approvals": {
                "text": "Initially OK'd for pediatric and young adult patients with a type of B-cell acute lymphoblastic leukemia (ALL).  | In 2018, OK'd for adults with r/r large B-cell lymphoma after two or more therapies.  | In 2022, Ok'd for r/r follicular lymphoma. [history](https://www.drugs.com/history/kymriah.html)",
                "collapsible": false
              },
              "Notes": {
                "text": "Invented by Carl June whose notable results NYT published [in 2011](https://www.nytimes.com/2011/09/13/health/13gene.html)",
                "collapsible": true
              }
            }
          },
          {
            "item": "Yescarta",
            "description": "(Gilead)   2nd US approved CAR-T in Oct 2017",
            "details": {
              "Approvals": {
                "text": "Cleared for several B-cell lymphomas including DLBCL & follicular lymphoma. | 2022 won earlier use in lymphoma. [history](https://www.drugs.com/history/yescarta.html)",
                "collapsible": false
              },
              "Notes": {
                "text": "Gilead bought Kite Pharma in 2017 for $12B to get its CAR-Ts.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Tecartus",
            "description": "(Gilead)   3rd CAR-T approved in July 2020",
            "details": {
              "Approvals": {
                "text": "First for mantle cell lymphoma, extended to acute lymphoblastic leukemia in 2021 [history](drugs.com/history/tecartus.html)",
                "collapsible": false
              },
              "Notes": {
                "text": "Slightly different version of Yescarta",
                "collapsible": false
              }
            }
          },
          {
            "item": "Breyanzi",
            "description": "(Bristol Myers)   4th CAR-T approved in Feb 2021",
            "details": {
              "Approvals": {
                "text": "For types of large B-cell lymphoma [history](https://www.drugs.com/history/breyanzi.html)",
                "collapsible": false
              },
              "Notes": {
                "text": "Targets CD-19.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Abecma",
            "description": "(Bristol Myers)   5th CAR-T approved in Mar 2021, 1st for multiple myeloma",
            "details": {
              "Approvals": {
                "text": "R/r multiple myeloma [history](https://www.drugs.com/history/abecma.html)",
                "collapsible": false
              },
              "Notes": {
                "text": "Targets B-cell maturation antigen (BCMA).",
                "collapsible": false
              }
            }
          },
          {
            "item": "Carvykti",
            "description": "(J&J/Legend Biotech)   6th CAR-T approved in Feb 2022, 2nd for multiple myeloma",
            "details": {
              "Approvals": {
                "text": "R/r multiple myeloma [history](https://www.drugs.com/history/carvykti.html)",
                "collapsible": false
              },
              "Notes": {
                "text": "Targets B-cell maturation antigen (BCMA).",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "Bispecific antibodies",
        "items": [
          {
            "item": "Blincyto",
            "description": "First to win approval in 2014.",
            "details": {
              "Maker": {
                "text": "Amgen",
                "collapsible": false
              },
              "Notes": {
                "text": "These bispecific drugs work by binding simultaneously to proteins on tumor cells and on T cells, inducing an immune attack on cancer. The first drugs to gain approval treated leukemia and lymphoma based on protein targets distinctive to those diseases.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Hemlibra",
            "description": "2nd bispecific antibody approved in U.S.",
            "details": {
              "Maker": {
                "text": "Roche",
                "collapsible": false
              },
              "Notes": {
                "text": "Binds to two proteins important in blood clotting to help stem bleeding in people with hemophilia. Targets: CD19 x CD3",
                "collapsible": false
              }
            }
          },
          {
            "item": "Rybrevant",
            "description": "3rd bispecific antibody approved in U.S. in May 2021",
            "details": {
              "Maker": {
                "text": "J&J",
                "collapsible": false
              },
              "Notes": {
                "text": "The FDA approved Rybrevant to treat a specific mutation in a cancer-linked protein that’s thought to be present in about 2% of patients with non-small cell lung cancer. Targets: EGFR x cMET",
                "collapsible": false
              }
            }
          },
          {
            "item": "Vabysmo",
            "description": "Approved in Jan 2022, fourth FDA-approved therapy for “wet” age-related macular degeneration",
            "details": {
              "Maker": {
                "text": "Roche",
                "collapsible": false
              },
              "Notes": {
                "text": "4th FDA-approved therapy for “wet” age-related macular degeneration. VEGF x Ang-2",
                "collapsible": false
              }
            }
          },
          {
            "item": "Tecvayli",
            "description": "Approved in Oct 2022, first-of-its kind for multiple myeloma",
            "details": {
              "Maker": {
                "text": "J&J",
                "collapsible": false
              },
              "Notes": {
                "text": "Targets BCMA x CD3. One of a wave to target this protein found on malignant cells in multiple myeloma. GlaxoSmithKline was the first to target BCMA with an antibody-drug conjugate Blenrep OK'd in 2020. The CAR-T Abecma also targets BCMA. Tecvayli was J&J's 4th approved treatment for multiple myeloma.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Epkinly",
            "description": "Approved in May 2023",
            "details": {
              "Maker": {
                "text": "AbbVie",
                "collapsible": false
              },
              "Notes": {
                "text": "Relapsed or refractory diffuse large B-cell lymphoma (DLBCL). CD20 x CD3",
                "collapsible": false
              }
            }
          },
          {
            "item": "Lunsumio",
            "description": "Approved in Dec 2022",
            "details": {
              "Maker": {
                "text": "Roche",
                "collapsible": false
              },
              "Notes": {
                "text": "Follicular lymphoma. CD20 x CD3",
                "collapsible": false
              }
            }
          },
          {
            "item": "Talquetamab",
            "description": "Experimental",
            "details": {
              "Maker": {
                "text": "J&J",
                "collapsible": false
              },
              "Notes": {
                "text": "Targets GPR5CD x CD3",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "RSV vaccines",
        "items": [
          {
            "item": "Abrysvo",
            "description": "FDA considering for adults and maternal use in 2023.",
            "details": {
              "Maker": {
                "text": "Pfizer",
                "collapsible": false
              },
              "Notes": {
                "text": "Advisers voted 14-0 and 10-4 (safety for infant use and a closer 7-4 for older adults use in separate 2023 votes, approvals due August and May, respectively.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Arexvy",
            "description": "First RSV vaccine to win U.S. approval, in May 2023.",
            "details": {
              "Maker": {
                "text": "GSK",
                "collapsible": false
              },
              "Notes": {
                "text": "Cleared only for use in adults 60 years or older.",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "Viral vectors",
        "items": [
          {
            "item": "AAV",
            "description": "adeno-associated virus. Single stranded DNA",
            "details": {
              "Integration": {
                "text": "Episomal, with 0.1% genomic. You can't say liver directed AAV gene therapy will be permanent, doesn't survive cell division or apoptosis. Max insertion size: Less than 8kb",
                "collapsible": false
              },
              "Notes": {
                "text": "AAVs are widely used in gene therapy experiments and involved in most of the marketed genetic medicines for inherited disorders, but are constrained by their small size, making many diseases difficult to reach.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Adenovirus",
            "description": "double stranded DNA",
            "details": {
              "Integration": {
                "text": "Episomal. Short term effect of 1-2 weeks. 5kb",
                "collapsible": false
              }
            }
          },
          {
            "item": "Lentivirus",
            "description": "RNA",
            "details": {
              "Integration": {
                "text": "Genomic. Life-long transgene expression. 8-12kb",
                "collapsible": false
              }
            }
          },
          {
            "item": "Herpes Simplex Virus",
            "description": "double stranded DNA",
            "details": {
              "Integration": {
                "text": "Episomal. Targets are CNS, muscle, heart, liver. Large packaging capacity between 30-50kb",
                "collapsible": false
              },
              "Examples": {
                "text": "Krystal Biotech's Vyjuvek, first topical gene therapy OK'd in May 2023, for \"butterfly children\" with dystrophic epidermolysis bullosa.",
                "collapsible": false
              }
            }
          }
        ]
      },
      {
        "group": "Gene therapy for inherited disease",
        "items": [
          {
            "item": "Luxturna",
            "description": "1st gene therapy approved in U.S. for an inherited disorder (Spark Therapeutics)",
            "details": {
              "Notes": {
                "text": "[OK'd in Dec 2017](https://www.biopharmadive.com/news/fda-spark-blindness-treatment-gene-therapy-luxturna/513431/) for hereditary form of vision loss caused by mutations in a gene known as RPE65, which leads to impaired or altogether absent function from its encoded protein. | Individuals who have RPE65 mutation-associated retinal dystrophy experience vision loss in childhood or adolescence, progressing to complete blindness in some patients. | Two CAR-T gene therapy treatments preceded its approval, but it was the first gene therapy directly administered for an inherited disease caused by a genetic mutation.",
                "collapsible": true
              }
            }
          },
          {
            "item": "Zolgensma",
            "description": "2nd GT for an inherited disorder in U.S. (Novartis)",
            "details": {
              "Notes": {
                "text": "Gene therapy for rare condition called spinal muscular atrophy [OK'd in 2019](https://www.biopharmadive.com/news/novartis-gene-therapy-zolgensma-approved-fda/554961/) | The FDA approved Zolgensma for pediatric patients under the age of two with bi-allelic mutations in the SMN1 gene. | Novartis estimated the treatable patient population +1,000 in the U.S.",
                "collapsible": false
              }
            }
          },
          {
            "item": "Zynteglo",
            "description": "xxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "Maker": {
                "text": "xxxxxxxxxxxxx",
                "collapsible": false
              },
              "Notes": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "Skysona",
            "description": "xxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "Maker": {
                "text": "xxxxxxxxxxxxx",
                "collapsible": false
              },
              "Notes": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "Hemgenix",
            "description": "xxxxxxxxxxxxxxxxxxxxx",
            "details": {
              "Maker": {
                "text": "xxxxxxxxxxxxx",
                "collapsible": false
              },
              "Notes": {
                "text": "xxxxxxxxxxxxxxxxxxxxx",
                "collapsible": false
              }
            }
          },
          {
            "item": "Vyjuvek",
            "description": "first topical (and redosable) gene therapy, for dystrophic epidermolysis bullosa. Sixth GT for inherited approved.",
            "details": {
              "Maker": {
                "text": "Krystal Biotech",
                "collapsible": false
              },
              "Notes": {
                "text": "Approved May 2023",
                "collapsible": false
              }
            }
          }
        ]
      }
    ]
  }
]
